Glenmark Introduces Tevimbra in India for Advanced Cancer Care

In a significant milestone for the evolution of cancer care in India, Glenmark Pharmaceuticals announced the launch of Tevimbra (tislelizumab), an innovative immune-oncology drug of the Central Drugs Standard Control Organization (CDSCO). 

Tevimbra is Glenmark's first initiation into immune-oncology in India - a space that is set to change treatment pathways for hard-to-treat cancers. 

Tevimbra is a monoclonal antibody originally developed by global oncology company BeiGene (now BeOne Medicines), for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), and esophageal squamous cell carcinoma (ESCC). In India, NSCLC makes up about 80% of all lung cancer, while ESCC is the most common form of esophageal cancer, making Tevimbra's entrance an important one for these specific patient group.

Tevimbra has already received approvals across the United States, EU, Australia, and China, and is currently approved in 46 countries, with over 1.5 million patients treated globally. What makes Tevimbra unique is its precision targeting of PD-1 receptors, restoring T-cell function with minimal immune suppression. Its global clinical programme includes nearly 14,000 patients, across 70 trials, and 21 pivotal studies.

Also Read: Role of Optical Imaging in Early Cancer Detection and Treatment

“With the launch of Tevimbra, Glenmark is delivering on its commitment to transform cancer care in India by making globally benchmarked immunotherapies more accessible,” said Alok Malik, president and business head – India formulations, Glenmark Pharmaceuticals Ltd.